40. [IF=4.6] Tianming Lu et al."Inhibition of ALDOA and ENO1-mediated Glycolysis of Oridonin as a Novel Anti-tumor Strategy of Non-small Cell Lung Cancer."Advanced Therapeutics".2024 Apr;:2400027 39. [IF=5] Shiying Ye et al."Oridonin promotes RSL3-induced ferroptosis in breast cancer cells by regulating the oxidative stress signaling pathway JNK/Nrf2/HO-1."EUROPEAN JOURNAL OF PHARMACOLOGY".2024 Apr;:176620 38. [IF=3.8] Zhang Feifan et al."Oridonin-induced ferroptosis and apoptosis: a dual approach to suppress the growth of osteosarcoma cells."BMC CANCER".2024 Dec;24(1):1-11 37. [IF=4.5] Lunji Wang et al."Antibacterial Mechanisms and Antivirulence Activities of Oridonin against Pathogenic Aeromonas hydrophila AS 1.1801."Microorganisms".2024 Feb;12(2):415 36. [IF=9.965] Mengru Cai et al."Enhanced lysosomal escape of cell penetrating peptide-functionalized metal-organic frameworks for co-delivery of survivin siRNA and oridonin."JOURNAL OF COLLOID AND INTERFACE SCIENCE.2023 Apr;: 35. [IF=2.602] ZHOU Wei et al."Preparation and characterization of an oridonin and γ-cyclodextrin complex."Food Science and Technology.2022 Aug;42: 34. [IF=5.811] 33. [IF=2.248] Yang Huiyu et al."Selective synergistic anticancer effects of cisplatin and oridonin against human p53-mutant esophageal squamous carcinoma cells."Anti-Cancer Drug. 2022 Jan;33(1):e444-e452 32. [IF=2.447] Yun Gui et al."Oridonin improves the therapeutic effect of lentinan on lung cancer."Exp Ther Med. 2021 Aug;22(2):1-9 31. [IF=3] Qu Lala et al."Phenotypic assessment and ligand screening of ETA/ETB receptors with label-free dynamic mass redistribution assay."N-S Arch Pharmacol. 2020 Jun;393(6):937-950 30. [IF=3.361] Mengru Cai et al."Functionalization of MOF-5 with mono-substituents: effects on drug delivery behavior."Rsc Adv. 2020 Oct;10(60):36862-36872 29. [IF=3.503] Lili Tian et al."Preliminary safety assessment of oridonin in zebrafish."Pharm Biol. 2019;57(1):632-640 28. [IF=3.591] Mengru Cai et al."Amino-functionalized Zn metal organic frameworks as antitumor drug curcumin carriers."New J Chem. 2020 Oct;44(41):17693-17704 27. [IF=6.543] Hong Mu-keng et al."Oridonin Alters Hepatic Urea Cycle via Gut Microbiota and Protects against Acetaminophen-Induced Liver Injury."Oxid Med Cell Longev. 2021;2021:3259238 26. [IF=0] Gan Zhao et al."Oridonin attenuates the release of pro-inflammatory cytokines in lipopolysaccharide-induced RAW264.7 cells and acute lung injury."Oncotarget. 2017 Sep 15; 8(40): 68153–68164 25. [IF=1.785] Tao Xu et al."Oridonin enhances in vitro anticancer effects of lentinan in SMMC‑7721 human hepatoma cells through apoptotic genes."Exp Ther Med. 2017 Nov;14(5):5129-5134 24. [IF=2.833] Tian Lili et al."Antiangiogenic effects of oridonin."Bmc Complem Altern M. 2017 Dec;17(1):1-15 23. [IF=3.361] Jushuang Li et al."Oridonin protects against the inflammatory response in diabetic nephropathy by inhibiting the TLR4/p38-MAPK and TLR4/NF-κB signaling pathways."Int Immunopharmacol. 2018 Feb;55:9 22. [IF=3.571] Xiangling Xiao et al."Oridonin inhibits gefitinib-resistant lung cancer cells by suppressing EGFR/ERK/MMP-12 and CIP2A/Akt signaling pathways."Int J Oncol. 2016 Jun;48(6):2608-2618 21. [IF=3.723] Yang Sun et al."Oridonin prevents epithelial-mesenchymal transition and TGF-β1-induced epithelial-mesenchymal transition by inhibiting TGF-β1/Smad2/3 in osteosarcoma."Chem-Biol Interact. 2018 Dec;296:57 20. [IF=5.722] Liu Qian-Qian et al."Oridonin inhibits pancreatic cancer cell migration and epithelial-mesenchymal transition by suppressing Wnt/β-catenin signaling pathway."Cancer Cell Int. 2016 Dec;16(1):1-8 19. [IF=5.959] Lu Ying et al."Oridonin exerts anticancer effect on osteosarcoma by activating PPAR-γ and inhibiting Nrf2 pathway."Cell Death Dis. 2018 Jan;9(1):1-16 18. Tian, L., Xie, K., Sheng, D. et al. Antiangiogenic effects of oridonin. BMC Complement Altern Med 17, 192 (2017). https://doi.org/10.1186/s12906-017-1706-3 17. Zhao G, Zhang T, Ma X, et al. Oridonin attenuates the release of pro-inflammatory cytokines in lipopolysaccharide-induced RAW264.7 cells and acute lung injury. Oncotarget. 2017;8(40):68153-68164. Published 2017 Jul 12. doi:10.18632/oncotarget.19249 16. Xiao, X., He, Z., Cao, W., Cai, F., Zhang, L., Huang, Q., Fan, C., Duan, C., Wang, X., Wang, J., Liu, Y."Oridonin inhibits gefitinib-resistant lung cancer cells by suppressing EGFR/ERK/MMP-12 and CIP2A/Akt signaling pathways". International Journal of Onco 15. Yang Sun, Xiubo Jiang, Ying Lu, Jianwei Zhu, Lisha Yu, Bo Ma, Qi Zhang, Oridonin prevents epithelial-mesenchymal transition and TGF-β1-induced epithelial-mesenchymal transition by inhibiting TGF-β1/Smad2/3 in osteosarcoma, Chemico-Biological Interactions, 14. Jushuang Li, Liping Bao, Dongqing Zha, Lian Zhang, Ping Gao, Juan Zhang, Xiaoyan Wu, Oridonin protects against the inflammatory response in diabetic nephropathy by inhibiting the TLR4/p38-MAPK and TLR4/NF-κB signaling pathways, International Immunopharmaco 13. Cai, Mengru, et al. "Amino-functionalized Zn metal organic frameworks as antitumor drug curcumin carriers." New Journal of Chemistry 44.41 (2020): 17693-17704.DOI https://doi.org/10.1039/D0NJ03680C 12. 王倩,纠敏,孟媛媛,孔铭杰,殷成芮,汪伦记.冬凌草甲素/壳聚糖复合膜对冰鲜鸡胸肉的保鲜效果[J].食品与机械,2021,37(03):125-130. 11. 李峥, 王强, 张晓莉. 蓝萼香茶菜提取溶剂的选择及其耐缺氧作用研究[J]. 中华中医药学刊, 2012, 030(006):1375-1377. 10. 何中维 肖香玲 蔡芬 张亮 黄秋月 段超 刘莹.冬凌草甲素逆转人胃癌细胞SGC 7901/DDP顺铂耐药的作用及机制研究[J].湖北医药学院学报 2016 35(03):261-265+226. 9. 尚曙玉 张铁山 郝海军 等. 冬凌草甲素磷脂复合物不同制剂在SD大鼠体内生物利用度的比较[J]. 中药材 2019 v.42;No.422(04):170-173. 8. 杜利月 郭留城 郝海军 等. 冬凌草甲素渗透泵片制备工艺研究及体外评价[J]. 中药材 2018 v.41；No.407(01):173-176. 7. 田丽莉 盛东来 朱国福. 冬凌草甲素抑制血管生成活性及作用机制[J]. 中国实验方剂学杂志 2016 022(005):166-171. 6. 纠敏 闫鹏 闫国庆 等. 冬凌草甲素对金黄色葡萄球菌的抑菌作用机制[J]. 江苏农业科学 2019 47(07):202-206. 5. 纠敏 闫鹏 李晶晶 等. 冬凌草甲素对金黄色葡萄球菌生物膜的抑制机制[J]. 微生物学通报 2020 v.47(05):250-256. 4. 田丽莉 朱国福 盛东来. 冬凌草甲素对人脐静脉内皮细胞的抑制作用[J]. 温州医学院学报 2017 047(012):880-883 887. 3. 肖香玲 何中维 黄秋月 季娟丽 张云飞 刘莹.冬凌草甲素下调EGFR/ERK/MMP-12和CIP2A/Akt信号通路抑制gefitinib耐受的非小细胞肺癌的转移[J].湖北医药学院学报 2016 35(06):536-542+629. 2. 纠敏 孟媛媛 王倩 等. 冬凌草甲素/壳聚糖复合膜的性能和结构表征[J]. 食品与发酵工业 2019 045(024):119-123. 1. 汪伦记 许美秋 纠敏 等. 冬凌草提取物对金黄色葡萄球菌生物膜形成的抑制作用[J]. 天然产物研究与开发 2017 029(006):1000-1005.